|
|
|
|
| LEADER |
02174nam a2200325 u 4500 |
| 001 |
EB001865315 |
| 003 |
EBX01000000000000001029395 |
| 005 |
00000000000000.0 |
| 007 |
tu||||||||||||||||||||| |
| 008 |
190504 r ||| eng |
| 245 |
0 |
0 |
|a Pharmacoeconomic review report: Ocrelizumab (Ocrevus) (Hoffmann-La roche limited)
|h Elektronische Ressource
|
| 246 |
3 |
1 |
|a Pharmacoeconomic review report for Ocrelizumab
|
| 246 |
3 |
1 |
|a Ocrelizumab (Ocrevus) (Hoffmann-La roche limited)
|
| 260 |
|
|
|a Ottawa (ON)
|b CADTH
|c 2017, December 2017
|
| 300 |
|
|
|a 1 PDF file (37 pages)
|b illustrations
|
| 505 |
0 |
|
|a Includes bibliographical references
|
| 653 |
|
|
|a Antibodies, Monoclonal, Humanized / economics
|
| 653 |
|
|
|a Multiple Sclerosis, Relapsing-Remitting / drug therapy
|
| 653 |
|
|
|a Canada
|
| 653 |
|
|
|a Cost-Benefit Analysis
|
| 653 |
|
|
|a Antibodies, Monoclonal, Humanized / therapeutic use
|
| 710 |
2 |
|
|a Canadian Agency for Drugs and Technologies in Health
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b NCBI
|a National Center for Biotechnology Information
|
| 490 |
0 |
|
|a CADTH common drug review
|
| 500 |
|
|
|a "Version 1.0."
|
| 856 |
4 |
0 |
|u https://www.ncbi.nlm.nih.gov/books/NBK534388
|3 Volltext
|n NLM Bookshelf Books
|3 Volltext
|
| 082 |
0 |
|
|a 140
|
| 082 |
0 |
|
|a 330
|
| 520 |
|
|
|a Ocrelizumab (Ocrevus) is a recombinant humanized monoclonal antibody that selectively targets and depletes B cells that express CD20, which are thought to contribute to the inflammatory and neurodegenerative pathogenesis of multiple sclerosis (MS). Ocrelizumab is indicated for the treatment of adult patients with relapsing-remitting multiple sclerosis (RRMS). It is available in 300 mg single-use vials for infusion. It is recommended that an initial 600 mg dose be administered as two separate intravenous (IV) infusions (initial 300 mg infusion followed by a second 300 mg infusion two weeks later), with subsequent ocrelizumab doses administered as single 600 mg IV infusions every six months. At the manufacturer's submitted unit price of $8,150 per 300 mg vial, ocrelizumab costs $32,600 per patient per year. The manufacturer's reimbursement request is per the Health Canada indication
|